APONTIS PHARMA

The Single Pill Company

9M 2021 Results

Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by APONTIS PHARMA AG (the "Company"), is not an offer to sell any securities or an invitation to purchase securities or the solicitation of an offer to buy securities. This Presentation is not an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is subject to updating, completion, revision and verification.

No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law and regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of its respective directors, officers, partners, employees, agents, affiliates, representatives or advisers, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation.

None of the Company, its affiliates and advisers, agents and/or any other party undertakes or is under any duty to update the Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation.

The Presentation includes statements that are, or may be deemed to be, forward-looking statements. These statements are based on the current views, expectations and assumptions of the management of the Company and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those described in such statements due to, among other things, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations and competition from other companies, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, affecting the Company and other factors. The Company does not assume any obligations to update any forwardlooking statements. The Presentation includes statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Company's business and markets. Unless otherwise indicated, such information is based on analysis by the Company of multiple sources, including certain studies commissioned from third parties (the "Market Reports"). The Market Reports may include and be based on, amongst other things, information obtained from primary interviews and field visits conducted by third parties with industry experts and participants, third parties' secondary market research and internal financial and operational information supplied by, or on behalf of, the Company, as well as information obtained from (i) data providers; (ii) industry associations and country organizations; and (iii) publicly available information from other sources, such as information publicly released by the Company's competitors. To the extent available, the industry, market and competitive position data contained in the Presentation has come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained in them have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in the Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the markets in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in the Presentation. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described in the Presentation. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and, to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

The distribution of this Presentation in certain jurisdictions is restricted by law. Therefore, it must not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. All trademarks remain the property of their respective owners. By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person or reproduce or publish this document, in whole or in part, for any purpose; and (ii) you have read and agree to comply with the contents of this notice.

APONTIS PHARMA Management's Presenters

Karlheinz Gast

Chief Executive Officer

Strategy
Marketing & Sales
Human Resources
Finance
Investor Relations

Thomas Milz

Chief Product Officer

Business Development
Market Access
Medical & Regulatory Affairs
Product Development
Supply Chain

"Drug non-compliance is a stealth epidemic exacting a heavy toll on the healthcare system – our broad portfolio of Single Pills is designed to help tackle this epidemic"

IPO at Frankfurt Stock Exchange in May 2021

APONTIS PHARMA: The Single Pill Company

§ HQ: Monheim/ Rhein (GER)
§ Among Europe's leading pharmaceuticaland chemical regions
§ German heritage business of SCHWARZ PHARMA
§ Formed in 2018 Acquisition by PARAGON PARTNERS from publicly listed UCB

§ Unique salesforce – 130 sales reps § Target group 23k physicians § Total visits > 200k p.a.

§ Lean business model (no production or storage)

§ Integrated pharma business (R&D, regulatory, quality, medical, market access, sales and beyond)
§ Broad network with researchbased pharmaceutical companies
§ Environmental: Focusing on decrease in wasteand emissions
ESG 1st § Social: Fostering diversity as well as employee well-being and health promotion
§ Governance: Following GCGC and pharmaceutical industry code of conduct
§ Single Pill leader in the German market with a focus on cardiovascular diseases ("CVD"), diabetes and respiratory diseases
§ More effective therapeutical effect proven in START Study

9M 2021

§ EURm 36.1 revenues (+37%)

§ EURm 4.4 EBITDA adj. (+EURm 5.7)
§ 232k Single Pill patients (+74%)

"No More Grandma's Muesli" – Single Pill Therapy on the Rise

Single Pills' High Effectiveness and Increased Health Benefits Confirmed

§ 60,000 participants
§ Led by IPAM/ INGRESS Institute based on AOK PLUS health insurance data
§ Data on adherence collected over 1 year
§ 7 different Single Pills and 8 clinical outcomes

Key findings:

ü Greater adherence to therapy
ü Better prognosis for patients
ü Lower overall patient cost

Notes: (1) Reduction is understood as a change up to the respective percentage figure indicated and compared to event rate of conventional treatment with multi pill therapy (2) Cost reduction is reflecting total costs (hospital costs, office-based costs, medication costs and costs for curative means and aids) per patient per year in Germany Source: START Study, IPAM / INGRESS Institute

User Market Tailwinds: Ageing Society and Rise of Chronic Diseases

Continuing trend and need for medical attention
Prevalence of chronic diseases rises with age
The increase in older people will increase the Single Pills demand drastically, since they profit though ease of use and limit of side-effects

30- 40- 50- 60- 70- Rise of Chronic Diseases Like Hypertension

Repeated Purchases

APONTIS has a focus on Single Pills for CVD (e.g. hypertension)
Chronic and incurable illness patients buy drug on a regular basis

Hypertension – An Epidemic

CVD is the leading cause of death in Germany
A large untapped market for APONTIS

Reached necessary target blood pressure 9.0m

Accurately diagnosed 21.8m
Germans suffering from hypertension 35.0m

German population 83.8m

AXA Recommends APONTIS PHARMA'S Single Pills to Clients

AXA feedback on campaign success as of August: "Countless direct contacts from patients and significant increase in Single Pill prescriptions - continuation of further cooperation activities"

APONTIS Has a Unique and Powerful Position in the Single Pill Market

Sales Force with Excellent Access to Physicians Driven by Holistic Approach

Sales force position : Entry barrier and key strength

Strongest sales force in Germany with 130 reps leveraging unique multi channel approach
Experience and good relationship to 23,000 physicians in Germany

Value-adding services "beyond the pill" for patients and physicians

Optimization of patient management
Optimization of doctors' office processes
Consulting on hygiene certification
Cardio-pulmonary reanimation training

Strong Share of Voice Position in Single Pill Market*

Next Steps Towards Growth Following the Successful IPO

FY21 Forecast Raised and Well on Way to Medium-Term Target of around 30%

Notes: * 2020 y-o-y Other decline following expiry of DAFIRO co-marketing; no impact in current financial year / Group figures for 9M 2021 are unaudited. Rounding differences may occur. Source: Company information, unaudited financials

APONTIS PHARMA: The Single Pill Strategy – Repeating Success

Many more commonly used combinations are only available as loose combinations – APONTIS can leverage existing know-how and market access to new Single Pills

Source: Company information

The Development of a Single Pill: Many Steps – One Goal

Short-term Pipeline: Accelerating the Development of Single Pills

1 Field of application	Tonotec Lipid	RosuvaEze	Caramlo HCT	Caramlo Lipid
Planned market launch	Q1 2022	Q4 2022	July 2023	December 2023
Status	§ Registration submission process already started	§ Negotiations with supplier, already developed in Europe	§ Dosages split across two suppliers, development ongoing	§ Supplier contract signed, development ongoing
Competitive environment	§ No other Single Pill provider with this combination	§ Other Single Pill provider with this combination	§ No other Single Pill provider with this combination	§ No other Single Pill provider with this combination
Patient potential²	661k	151k	330k	486k
Total development cost	EURm 1.9	EURm 0.0 (exclusive licensing agreement)	EURm 1.3	EURm 2.5
Mid-term annual revenue potential	EURm 6.5	EURm 2.5	EURm 9	EURm 3.6

Short-term Pipeline: Further Expansion of Single Pill Portfolio

1 Field of application	AmloAtor	RosuASS
Planned market launch	Q1 2022	Q1 2022
Status	§ Marketing Authorisation § Marketing Authorisation transferred; production process in transferred; production process in preparation preparation § Trademark = ownership APONTIS § Trademark = ownership APONTIS
Competitive environment	§ No other Single Pill provider with this combination	§ No other Single Pill provider with this combination
Patient potential²	506k	100k
Total development cost	EURm 0.3 (exclusive licensing agreement)	EURm 0.4 (semi-exclusive licensing agreement)
Mid-term annual revenue potential	EURm 4.8	EURm 1.7

Notes: (1) Main application essential hypertension; (2) Patient potential: Number of patients with same substance class combination in loose form Source: Patient INSIGHTS Analytics (PIA). A web-based pharma tool from INSIGHT Health GmbH & Co. KG; Company information

Mid-term Development Pipeline: Continuous Market Opportunities

Single Pill	Product	Patient potential	Development costs (estimate in EURm)	Estimated launch (in years from now)	Revenue potential (Y5 after launch, in EURm)
Development candidates	1.	2,467	1.8 - 2.2	3.5	20.2
	2.	1,267	0.5 - 1.5	2.5	6.0
	3.	305	1.8 - 2.2	2.5	1.4 - 2.8
	4.	270	1.8 - 2.2	4.0	6.5
	5.	2,467	0.5 - 1.5	2.5	2.3
	6.	188	2.5 – 3.0	4.0	12.0
	7.	216	1.8 - 2.2	8.0	7.5
	8.	499	0.5 - 1.5	3.5	10.0
	9.	409	0.5 - 1.5	3.5	12.0
	…
Exclusive licensing agreements	1.	1,440	0.0	0.5	4.5 - 5.0
	2.	378	0.4	0.7	4.5 - 5.0
	3.	240	0.3	0.5	3.5 - 4.0
	…

Clear Target of +20 Single Pills Portfolio Generating Revenues in 2026

Source: Patient INSIGHTS Analytics (PIA). A web-based pharma tool from INSIGHT Health GmbH & Co. KG; Company information 20

Single Pill Revenues as Key Growth Driver for Dynamic Development

Note: Group figures for 9M 2021 are unaudited. Rounding differences may occur.

Operational Profitability Driven by Disproportionately Low Costs Rise in Face of Strong Increase in Revenues

Solid Financial Position: Well-Funded for Planned Activities

^• Increase in assets driven by IPO as well as increasing business activity

Decrease in non-current assets mainly due to scheduled amortization-related reduction of concessions, while capitalising advance payments on milestones
Equity ratio at 76.0% significantly improved
Liabilities decreased by more than half, in particular, liabilities to shareholders were completely reduced

APONTIS PHARMA on the Capital Market

Share price performance (IPO to date)

Share price information (IPO to date)

Issue Price		EUR 19.00
Low	4 June 2021	EUR 16.60
High	28 September 2021	EUR 27.80
Close	15 November 2021	EUR 22.80
Performance		+20.0%
Market Cap		EUR 193.8 Mio.

Investment Highlights

First mover and category leader in Germany for Single Pills with a focus on cardiovascular diseases ("CVD")
Most comprehensive Single Pill portfolio in the market protected by high entry barriers due to intellectual property, long lead times with development cycles of 3.5 - 5 years and best in class sales team
- Attractive growth prospects resulting from aging population, hypertension as a major chronic health issue and the high Single Pill adoption rates
€ %

1st

High visibility on growth driven by significant potential to increase market share with existing products and a full product pipeline with new Single Pill products to be launched short term as well as medium-term
Scalable business model with highly attractive unit economics to support 30% EBITDA margins in the medium-term
Strong strategic push to accelerate the commercialization and development of the product pipeline with attractive payback times per Single Pill product of 2 years on average

€

YOUR QUESTIONS PLEASE!

THANK YOU FOR YOUR ATTENTION!

[email protected] T: +49 2173 89 55 4900 F: +49 2173 89 55 1521

Alfred-Nobel-Str. 10 40789 Monheim am Rhein Deutschland

apontis-pharma.de

ESG criteria as integral part of APONTIS PHARMA'S DNA – EXTENSION EXISTING MISSION FOR SOCIETY

Less packaging: Single Pills save up to 66% of packaging; in addition, APONTIS PHARMA discontinuation of smaller package sizes
Waste recycling and reduction in offices
Corporate fleet: CO2 emission cap with binding limit according to Euro 6D emission standard
Reduction of paper consumption in offices
Production exclusively in Europe enables reduction of transports
Employee health and safety protection: burn-out risk analysis, health promotion initiatives, ergonomic workstations, corporate physicians
Help/contact point for problems counseling center
Strictly ensuring compliance with central labor rights
Diversity in the workplace
Hygiene seminars and CPR trainings in doctors' offices

Our Future Goals Our Future Goals Our Future Goals

Expansion of corporate fleet to include e-cars Promotion of community development and cultural customs (e.g., NGO orphanages, Christmas fairs)
Expansion of (medical training programs for employees
APONTIS PHARMA foundation to promote scientific research through awards
Compliance Officer appointed
Adherence to pharmaceutical industry association code of conduct
Strictly ensuring anti-corruption law for employees dealing with physicians
Acting in accordance with the German Corporate Governance Code
Regular visits of suppliers to ensure quality of products and sustainable manufacturing conditions
Continuous development of IT security
Introduction of code of conduct for employees
Implementation of ESG reporting

"At APONTIS PHARMA, our mission is not only to save lives, but we strive "together for a better life".

APONTIS PHARMA Management's long-standing track record in pharma

Karlheinz Gast Chief Executive Officer Joined 1997

33 Years in Pharma

Strategy
Marketing & Sales
Human Resources
Finance
Investor Relations

Thomas Milz Chief Product Officer Joined 1991

30 Years in Pharma

Business Development
Market Access
Medical and Regulatory Affairs
Product Development
Supply Chain

Dr. med. Matthias Wendl Head of Sales 19 Years in Pharma

Harald Weyand Head of Marketing 32 Years in Pharma

Extended Management

Dr. rer. nat. Susanne Endreß Head of Regulatory Affairs 26 Years in Pharma

Dr. med. Olaf Randerath Head of Medical Affairs 23 Years in Pharma